目的 探讨舒胆片联合拉氧头孢钠治疗急性胆囊炎的临床效果。方法 选取2016年1月-2017年6月就诊于青海大学附属医院的135例急性胆囊炎患者，随机分为对照组（67例）和治疗组（68例）。对照组静脉滴注注射用拉氧头孢钠，1.0 g溶解于250 mL生理盐水，2次/d。治疗组在对照组治疗基础上口服舒胆片，5片/次，3次/d。两组患者均连续治疗2周。观察两组的临床疗效，比较两组治疗前后临床症状积分、视觉模拟（VAS）评分、世界卫生组织生活质量量表（WHOQOL-BREF）评分、血清因子水平、胆囊张力和胆囊壁厚度的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是86.56%、97.06%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者临床症状积分和VAS评分均显著降低，但WHOQOL-BREF评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组患者临床症状积分和VAS评分显著低于对照组，WHOQOL-BREF评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清β-内啡肽（β-EP）、白细胞介素-6（IL-6）、瘦素（LEP）、胆囊张力均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组β-EP、IL-6、LEP、胆囊张力显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 舒胆片联合拉氧头孢钠治疗急性胆囊炎临床疗效显著，能显著改善患者临床症状及生活质量，调节炎症因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Shudan Tablets combined with latamoxef sodium in treatment of acute cholecystitis. Methods Patients (135 cases) with acute cholecystitis in Affiliated Hospital of Qinghai University from January 2016 to June 2017 were randomly divided into control (67 cases) and treatment (68 cases) groups. Patients in the control group were iv administered with Latamoxef Sodium for injection, 1.0 g dissolved in normal saline 250 mL, twice daily. Patients in the treatment group were po administered with Shudan Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of clinical symptom score, visual analogue (VAS) score, WHOQOL-BREF score, serum factors level, gallbladder tension and gallbladder wall thickness in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 86.56% and 97.06%, and there were differences between two groups (P<0.05). After treatment, clinical symptom score and VAS score were significantly decreased in two groups, but WHOQOL-BREF score was significantly increased, and there were differences in the same group (P<0.05). After treatment, clinical symptom score and VAS score in the treatment group were lower than those in the control group, but WHOQOL-BREF score was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, β-EP, IL-6, LEP, and gallbladder tension were significantly decreased in two groups, and there were differences in the same group (P<0.05). After treatment, β-EP, IL-6, LEP, and gallbladder tension in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Shudan Tablets combined with latamoxef sodium has significant clinical efficacy in treatment of acute cholecystitis, and can significantly improve the clinical symptoms and life quality, and regulate the level of inflammatory factors, which has a certain clinical application value.